Výsledky vyhledávání

ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease

Publikováno v: Nature Aging, 1(6), 521-534. Springer
Novak, P, Kovacech, B, Katina, S, Schmidt, R, Scheltens, P, Kontsekova, E, Ropele, S, Fialova, L, Kramberger, M, Paulenka-Ivanovova, N, Smisek, M, Hanes, J, Stevens, E, Kovac, A, Sutovsky, S, Parrak, V, Koson, P, Prcina, M, Galba, J, Cente, M, Hromadka, T, Filipcik, P, Piestansky, J, Samcova, M, Prenn-Gologranc, C, Sivak, R, Froelich, L, Fresser, M, Rakusa, M, Harrison, J, Hort, J, Otto, M, Tosun, D, Ondrus, M, Winblad, B, Novak, M & Zilka, N 2021, ' ADAMANT : a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer’s disease ', Nature Aging, vol. 1, no. 6, pp. 521-534 . https://doi.org/10.1038/s43587-021-00070-2

Alzheimer’s disease (AD) pathology is partly characterized by accumulation of aberrant forms of tau protein. Here we report the results of ADAMANT, a 24-month double-blinded, parallel-arm, randomized phase 2 multicenter placebo-controlled trial of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f9207a075a751b59f0b0c380b710aaf1
https://research.vumc.nl/en/publications/61abe2cc-82ad-4ac3-93be-d1cbc548881b

Zobrazit plný text záznamu

miRNAs as biofluid markers for diagnostics of Alzheimer's disease: recent status and perspectives

Autor: Peter Filipcik, Peter Koson, Nina Kosikova, Viera Cigánková, Martin Cente

Publikováno v: General physiology and biophysics. 37(5)

After many decades of research in the field of neurodegeneration, we have no effective cure for Alzheimer's disease (AD), a major form of dementia. It is mainly due to the lack of early, reliable and sensitive biomarkers and incomplete understanding

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1d8c52d048267d154b5d1e172f1e13c0
https://pubmed.ncbi.nlm.nih.gov/30307401

Zobrazit plný text záznamu

First transgenic rat model developing progressive cortical neurofibrillary tangles

Autor: Norbert Zilka, Juraj Kucerak, Petr Novak, Peter Filipcik, Ondrej Bugos, Peter Koson, Michal Novak

Publikováno v: Neurobiology of Aging. 33:1448-1456

Neurofibrillary degeneration induced by misfolded protein tau is considered to be one of the key pathological hallmarks of Alzheimer's disease (AD). In the present study, we have introduced a novel transgenic rat model expressing a human truncated ta

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::866c18ad38fa4446a6092c358dc24b3e
https://doi.org/10.1016/j.neurobiolaging.2010.10.015

Zobrazit plný text záznamu

Truncated tau expression levels determine life span of a rat model of tauopathy without causing neuronal loss or correlating with terminal neurofibrillary tangle load

Autor: Michal Novak, Peter Koson, Branislav Kovacech, Andrej Kovac, Norbert Zilka, Peter Filipcik, Miroslava Korenova

Publikováno v: European Journal of Neuroscience. 28:239-246

We have previously demonstrated in a transgenic rat model of tauopathy that human misfolded truncated tau derived from Alzheimer's disease suffices to drive neurofibrillary degeneration in vivo. We employed this model to investigate the impact of tru

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::adf9d5d463cf601e5b359b348b8fc9c9
https://doi.org/10.1111/j.1460-9568.2008.06329.x

Zobrazit plný text záznamu

Plný text ve formátu HTML

Neurodegeneration caused by expression of human truncated tau leads to progressive neurobehavioural impairment in transgenic rats

Autor: Norbert Zilka, Miroslava Hrnkova, Michal Novak, Peter Koson, Zuzana Minichova

Publikováno v: Brain Research. 1130:206-213

Human truncated tau protein is an active constituent of the neurofibrillary degeneration in sporadic Alzheimer's disease. We have shown that modified tau protein, when expressed as a transgene in rats, induced AD characteristic tau cascade consisting

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e28b381d9ffda3c92f5eb3388d605caa
https://doi.org/10.1016/j.brainres.2006.10.085

Zobrazit plný text záznamu

The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases

Publikováno v: Frontiers in Neurology
Frontiers in Neurology, Frontiers, 2015, 6, ⟨10.3389/fneur.2015.00216⟩
Frontiers in Neurology, 6
Frontiers in Neurology, 6:216. Frontiers Media S.A.
Frontiers in Neurology.-Lausanne : Frontiers Media SA; 2015.-S.216:1-216:7.
Frontiers in Neurology, Vol 6 (2015)
Reijs, B L R, Teunissen, C E, Goncharenko, N, Betsou, F, Blennow, K, Baldeiras, I, Brosseron, F, Cavedo, E, Fladby, T, Froelich, L, Gabryelewicz, T, Gurvit, H, Kapaki, E, Koson, P, Kulic, L, Lehmann, S, Lewczuk, P, Lleo, A, Maetzler, W, de Mendonca, A, Miller, A M, Molinuevo, J L, Mollenhauer, B, Parnetti, L, Rot, U, Schneider, A, Simonsen, A H, Tagliavini, F, Tsolaki, M, Verbeek, M M, Verhey, F R J, Zboch, M, Winblad, B, Scheltens, P, Zetterberg, H & Visser, P J 2015, ' The central biobank and virtual biobank of BiOMarKaPD: a resource for studies on neurodegenerative diseases ', Frontiers in Neurology, vol. 6, 216 . https://doi.org/10.3389/fneur.2015.00216
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Frontiers in neurology 6, 216 (2015). doi:10.3389/fneur.2015.00216
FRONTIERS IN NEUROLOGY

Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multicenter study, funded by the EU Joint Programme-Neurodegenerative Disease Research, whic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::25028609cdf8e00930dd92b9add30835
http://europepmc.org/articles/PMC4606063

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání